These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 2341048)
1. Antitumor effects of antibody enzyme conjugates in combination with prodrugs. Senter PD Front Radiat Ther Oncol; 1990; 24():132-41; discussion 161-5. PubMed ID: 2341048 [No Abstract] [Full Text] [Related]
2. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Senter PD; Schreiber GJ; Hirschberg DL; Ashe SA; Hellström KE; Hellström I Cancer Res; 1989 Nov; 49(21):5789-92. PubMed ID: 2790791 [TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821 [TBL] [Abstract][Full Text] [Related]
4. Early studies of etoposide phosphate, a water-soluble prodrug. Budman DR Semin Oncol; 1996 Dec; 23(6 Suppl 13):8-14. PubMed ID: 8996570 [TBL] [Abstract][Full Text] [Related]
10. [Experimental study of anti-tumor effect with conjugates of monoclonal antibodies and hematoporphyrin derivative]. Xu SX; Wang NQ; Dong ZW Yao Xue Xue Bao; 1989; 24(6):401-6. PubMed ID: 2532854 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Senter PD; Saulnier MG; Schreiber GJ; Hirschberg DL; Brown JP; Hellström I; Hellström KE Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4842-6. PubMed ID: 3387440 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Ohsumi K; Hatanaka T; Nakagawa R; Fukuda Y; Morinaga Y; Suga Y; Nihei Y; Ohishi K; Akiyama Y; Tsuji T Anticancer Drug Des; 1999 Dec; 14(6):539-48. PubMed ID: 10834274 [TBL] [Abstract][Full Text] [Related]
13. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987 [TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Trail PA; Willner D; Bianchi AB; Henderson AJ; TrailSmith MD; Girit E; Lasch S; Hellström I; Hellström KE Clin Cancer Res; 1999 Nov; 5(11):3632-8. PubMed ID: 10589780 [TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Marecos E; Weissleder R; Bogdanov A Bioconjug Chem; 1998; 9(2):184-91. PubMed ID: 9548533 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933 [TBL] [Abstract][Full Text] [Related]
18. [Clinical application of monoclonal antibody-drug conjugates in colorectal carcinoma]. Takahashi T; Sakita M; Yamaguchi T; Kitamura K; Hata K; Noguchi A Gan To Kagaku Ryoho; 1988 May; 15(5):1702-9. PubMed ID: 2967049 [TBL] [Abstract][Full Text] [Related]
19. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Strawn LM; Kabbinavar F; Schwartz DP; Mann E; Shawver LK; Slamon DJ; Cherrington JM Clin Cancer Res; 2000 Jul; 6(7):2931-40. PubMed ID: 10914743 [TBL] [Abstract][Full Text] [Related]
20. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates. Huennekens FM Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]